BDA advises founder on sale of diagnostic biotech company CHROMagar SAS

BDA Partners is pleased to announce that the French company CHROMagar SAS, the pioneer in innovative chromogenic culture media solutions for diagnostic applications, has been sold to a Japanese chemicals company. BDA acted as the exclusive financial advisor to CHROMagar founder and shareholder, Dr. Alain Rambach. Terms of the transaction were not disclosed.

Dr. Alain Rambach, an inventor and pioneer since 1979 in chromogenic media technology, founded CHROMagar in 1993 to provide innovative chromogenic media solutions to improve and simplify traditional culture techniques. Established in Paris, not far from the famous Pasteur Institute where Dr. Rambach began his research career, CHROMagar is at the cutting edge of a diagnostic field that developed out of Dr. Rambach’s research in the late 1970s.

The acquisition of CHROMagar will give the buyer access to unique and innovative techniques to detect bacteria. The buyer has existing activities and knowledge in the field of chromogenic media, a strategic plan to expand its biotech business, and the capabilities to support CHROMagar’s continued growth.

Andrew Huntley, Senior Managing Director at BDA, said, “We are delighted to have helped CHROMagar close this successful transaction. It’s another example of the ongoing trend for Japanese corporates to make strategic acquisitions in Europe. Medical technology is a sector where we are experiencing significant appetite for cross-border transactions involving Japanese and other Asian parties.”